FLAG Therapeutics, Inc. is an early-stage oncology company focused on the development of therapies based on two investigational product platforms--the Anti-angiogenic/Anti-tubulin (AA/AT) platform and Folate-target Anti-cancer (FTAC) platform.
FLAG acquired exclusive worldwide rights to these two product platforms in November 2013 through a licensing agreement with Duquesne University. The platforms, which include thousands of investigational water-soluble small molecule compounds with the potential to treat multiple types of cancer, represent over 30 years of research conducted by Dr. Aleem Gangjee, distinguished professor of medicinal chemistry at the Duquesne University School of Pharmacy. Using creative medicinal chemistry and Structure Activity Relationship (SAR) analysis, Dr. Gangjee engineered the investigational compounds with the aim of creating new treatment options with greater safety and efficacy profiles than seen with existing therapeutics.
A Growing Company
FLAG's management team is currently comprised of two individuals each with over 20 years experience in the biotechnology/pharmaceutical industry. In the coming months, FLAG plans to further bolster its team with key personnel, including individuals with proven expertise in regulatory affairs, project management and research and development in chemistry, manufacturing and controls.
FLAG Therapeutics, Inc.
9168 Wooden Rd
Raleigh, North Carolina 27617-8203